论文部分内容阅读
目的观察吉西他滨联合腹腔热灌注化疗治疗晚期胰腺癌的临床疗效及安全性。方法选择晚期胰腺癌患者44例,随机化分为两组,其中试验组22例,接受吉西他滨1000 mg/m2,d1、d8,腹腔热灌注生理盐水500 mL+顺铂40 mg/m2,d2、d5、d9；对照组22例,接受吉西他滨1000 mg/m2,静脉滴注,d1、d8+顺铂40 mg/m2,静脉滴注,d1~3,两组均21 d为1周期,接受治疗2个周期后评价疗效。结果41例患者可进行疗效评估,两组临床疗效比较,试验组稳定率61.90%显著高于对照组稳定率45.00%,差异有统计学意义(P<0.05)；临床收益反应比较,实验组有效率85.7%也明显高于对照组为50.0%,差异有统计学意义(P <0.05)。结论吉西他滨联合腹腔热灌注化疗治疗晚期胰腺癌疗效较好,毒副反应小,止痛效果明显。“,”Obj ective]To observe the clinical efficacy and safety of gemcitabine combined with intraperitoneal hyperthermic perfusion chemotherapy in the treatment of advanced pancreatic cancer.[Methods]A total of 44 pa-tients with advanced pancreatic cancer were chosen and randomly divided into two groups.The experimental group (n=22)received gemcitabine 1000mg/m2 at d1 and d8,and intraperitoneal hyperthermic perfusion of saline 500ml plus cisplatin 40mg/m.2,at d2 ,d5 and d9 .The control group(n=22)received gemcitabine 1000mg/m2 intravenously at d1 and d8,and cisplatin 40mg/m.2 intravenously at d1~3 .The cycle was 21d.The efficacy was evaluated after 2 cycles of treatment.[Results]The efficacy of 41 patients was assessed.The efficacy was com-pared between two groups.The stability rate of experimental group was 61.90%,which was markedly higher than that in control group(45%),and there was significant difference(P <0.05).Clinical benefit response was com-pared between two groups.The effective rate of experimental group was 85.7%,which was obviously higher than that in control group(50.0%),and there was significant difference(P <0.05).[Conclusion]Gemcitabine com-bined with intraperitoneal hyperthermic perfusion chemotherapy in the treatment of advanced pancreatic cancer has good efficacy and obvious analgesic effect with small side reaction.